In 2009, Shoukhrat Mitalipov, Masahito Tachibana, and their team of researchers developed the technology of mitochondrial gene replacement therapy to prevent the transmission of a mitochondrial disease from mother to offspring in primates. Mitochondria contain some of the body's genetic material, called mitochondrial DNA. Occasionally, the mitochondrial DNA possesses mutations. Mitalipov and Tachibana, researchers at the Oregon National Primate Research Center in Beaverton, Oregon, developed a technique to remove the nucleus of the mother and place it in a donor oocyte, or immature egg cell, with healthy mitochondria. The resulting offspring contain the genetic material of three separate individuals and do not have the disease. Mitalipov and Tachibana's technology of mitochondrial gene replacement built on decades of research by different scientists and enables researchers to prevent the transmission of human mitochondrial diseases from mother to offspring.

Endoscopic fetoscopy is a minimally invasive surgical procedure performed during pregnancy that allows physicians to view the fetus in-utero. Physicians use endoscopic fetoscopy to evaluate, diagnose, and treat fetal abnormalities. Physicians use an endoscope, or a thin, flexible surgical device with a light attached to its end, to perform endoscopic fetoscopy procedures. In 1954, Björn Westin performed the first endoscopic fetoscopy in Sweden. Since Westin’s initial development of the procedure, interest in endoscopic fetoscopy has grown throughout the early part of the twenty-first century. In addition, the use of endoscopy has expanded beyond fetal medicine and has been introduced to other fields of medicine such as general surgery. Endoscopic fetoscopy allows surgeons to diagnose and correct fetal abnormalities that would otherwise result in fetal death before delivery or in lifelong impairment if treatment were delayed until after delivery.

NovaSure is a device for endometrial ablation, which is a procedure that removes the endometrium, that the US Food and Drug Administration, or FDA, approved for use on 28 September 2001. Endometrium is the tissue that lines the uterus. NovaSure destroys the endometrium by sending electric beams at the endometrium. Hologic, a medical technology company concerned with women’s health, developed NovaSure to treat menorrhagia, or heavy bleeding during menstruation. Menorrhagia is a common symptom of endometriosis. Endometriosis is the growth of the endometrium outside of the uterus. While NovaSure is not a treatment that doctors use to directly treat endometriosis, the procedure may help alleviate heavy bleeding during menstruation, which may improve a patient’s quality of life as heavy menstrual bleeding is often associated with high levels of anxiety and low levels of confidence.

In the nineteenth century, obstetricians in Europe began to construct devices to incubate infants in increasingly controlled environments. The infant incubator is a medical device that maintains stable conditions and a germ free environment for premature infants born before the thirty-seventh week of pregnancy. Records show that physicians had used infant incubators since 1835. However, Jean-Louis-Paul Denuce, a physician who worked in Bordeaux, France, first published about incubator technology in 1857. Carl Crede released his incubator model in Germany in 1860 and Stephane Tarnier further developed the model in 1884. The infant incubator technology provides a stable environment for premature infants and helps keep them alive.

Acid dissolution is a technique of removing a fossil from the surrounding rock matrix in which it is encased by dissolving that matrix with acid. Fossilized bone, though strong enough to be preserved for thousands or millions of years, is often more delicate than rock. Once a fossil is discovered, scientists must remove the fossil from its surroundings without damaging the fossil itself. Scientists have used chemicals to expose vertebrate fossils since the 1930s, and in the late 1990s Terry Manning, an amateur scientist and technician working in England, adapted the technology to dinosaur eggs. Manning used acid dissolution on dinosaur eggs to expose the embryos beneath the rock and fossil shell. Manning's acid dissolution enabled scientists to better study the remains of dinosaur embryos otherwise hidden beneath layers of eggshell and rock, revealing previously unrecorded aspects of dinosaur growth and development.

The measles, mumps, and rubella (MMR) vaccine was created by Maurice Hilleman in 1971 at the Merck Institute of Therapeutic Research, a pharmaceutical company in West Point, Pennsylvania. It combined three separate vaccines for measles, mumps, and rubella, common and sometimes fatal diseases. Measles causes a red skin rash and severe fevers that can be fatal. Mumps causes fever and swelling of the salivary glands in the mouth and jaw, while rubella causes milder fevers and skin rashes. Pregnant women that contract rubella sometimes pass the virus to their fetuses, causing congenital rubella syndrome, which results in malformations of the eyes, ears, heart, and brain in the fetuses. The MMR vaccine has protected millions of people from contracting the potentially deadly diseases of measles, mumps, and rubella, as well as prevented the development congenital rubella syndrome in the fetuses.

Exchange transfusion is the replacement of blood from newborn infants with elevated bilirubin level in their blood stream with donor blood containing normal bilirubin levels. Newborn infants that experience jaundice, the yellowing of the skin and eyes, have a buildup of bilirubin, a chemical that occurs during red blood cell breakdown, or hemolysis. Exchange transfusion is a therapy developed throughout the 1940s by Louis Diamond and a group of surgeons at the Children’s Medical Center in Boston, Massachusetts. During exchange transfusion, a physician inserts a plastic tube called a catheter through the umbilical vein of the infant to slowly remove infant blood and sequentially replace it with donor blood. Exchange transfusion was the first definitive treatment for hyperbilirubinemia in the US and it helped reduce the incidence of kernicterus, a type of brain damage caused by elevated bilirubin levels.

The Guthrie test, also called the PKU test, is a diagnostic tool to test infants for phenylketonuria a few days after birth. To administer the Guthrie test, doctors use Guthrie cards to collect capillary blood from an infant’s heel, and the cards are saved for later testing. Robert Guthrie invented the test in 1962 in Buffalo, New York. Phenylketonuria (PKU) is a congenital birth abnormality in which toxic levels of the amino acid phenylalanine build up in the blood, a process that affects the brains in untreated infants. Guthrie’s test detects phenylalanine in the blood of newborns, enabling for early diagnosis of PKU. Early diagnoses of PKU prevent the development of mental disabilities in the thousands of individuals affected each year.

Noninvasive fetal aneuploidy detection technology allows for the detection of fetal genetic conditions, specifically having three chromosomes, a condition called aneuploidy, by analyzing a simple blood sample from the pregnant woman. Dennis Lo and Rossa Chiu researched methods of detection of aneuploidies in the early twenty-first century. Their research has been specifically applied to three trisomies, trisomy twenty-one known as Down syndrome, trisomy eighteen known as Edwards Syndrome, and trisomy thirteen known as Patau Syndrome. Prior to the ability to detect fetal DNA in a pregnant woman’s blood, physicians performed amniocentesis or chorionic villus sampling, two techniques that increase the risk of spontaneous abortion. Noninvasive detection of trisomy twenty-one, eighteen, and thirteen technology allows for a more accurate and safer detection of those conditions than methods available before.

In 1952 Virginia Apgar, a physician at the Sloane Women’s Hospital in New York City, New York, created the Apgar score as a method of evaluating newborn infants’ health to determine if they required medical intervention. The score included five separate categories, including heart rate, breathing rate, reaction to stimuli, muscle activity, and color. An infant received a score from zero to two in each category, and those scores added up to the infant’s total score out of ten. An infant with a score of ten was healthy, and those with low scores required medical attention at birth. Apgar originally used the score to determine how infants responded to the pain-relieving drugs given to pregnant women during labor. But it also served to determine when the infant required medical assistance, especially oxygen resuscitation. As of 2016, nearly every hospital in the world uses an updated Apgar score to evaluate the health of newborn infants. The Apgar score has allowed for medical personnel to evaluate an infant directly after birth on an objective scale to determine whether that infant could benefit from possibly life-saving medical intervention.